Increased incidence of co-trimoxazole-induced rash in patients on systemic corticosteroid treatment for toxicity associated with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Increased incidence of co-trimoxazole-induced rash in patients on systemic corticosteroid treatment for toxicity associated with immune checkpoint inhibitors

Published:2024-05-16 Issue:3 Volume:191 Page:465-467
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:

Author:

Yiu Daniel¹,Aguilar-Duran Silvia²,Edwards Charlotte³,Chauhan Dharmisha²,Furness Andrew²,Turajlic Samra²⁴,Larkin James²,Fearfield Louise³,Heelan Kara²^ORCID

Affiliation:

1. Solihull Dermatology Department, University Hospitals Birmingham NHS Foundation Trust , Birmingham , UK

2. Royal Marsden Hospital , London , UK

3. Department of Dermatology, Chelsea and Westminster Hospital NHS Foundation Trust , London , UK

4. Cancer Dynamics Laboratory, Francis Crick Institute , London , UK

Abstract

Our cross-sectional study demonstrates that there is a high rate of co-trimoxazole-induced drug rash in patients treated for immune-related adverse events, with those developing rash appearing to have a reduced survival.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljae202/58199698/ljae202.pdf

Reference8 articles.

1. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Haanen;Ann Oncol,2022

2. Rates of cutaneous reactions to drugs;Bigby;Arch Dermatol,2001

3. Cutaneous manifestations associated with immune checkpoint inhibitors;Watanabe;Front Immunol,2023

4. Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?;Hammond;Clin Exp Allergy,2022